Regenxbio Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
7.37
0.22
(3.08%)
Volume:
680,534
52 week range:
6.56 - 28.80
Market Cap:
354.247M
Company Description:
REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.